Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
VCP-Eribulin
0 ImagesCat. No.: HY-128871CAS No.: 2130869-17-7VCP-Eribulin is a bioactive molecule-linker conjugate designed for ADCs (Drug-Linker Conjugates for ADC), formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442). Eribulin is a unique microtubule inhibitor exhibiting antitumor activity. VCP-Eribulin can be utilized for antibody conjugation.
-
AV-DL055
0 ImagesCat. No.: HY-183558CAS No.: 3107874-31-4
-
m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag
0 ImagesCat. No.: HY-158348CAS No.: 2553413-13-9m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag is a drug-linker conjugate for ADC.
-
Exatecan-(D-2,4-DHB)-NH2-AA(bPEG8)-Mal
0 ImagesCat. No.: HY-183594CAS No.: 3037373-65-9Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal is a linker-payload conjugate. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal contains the linker D-2,4-DHB-NH2-AA(bPEG8)-Mal (HY-183595) and the cytotoxic agent Exatecan (HY-13631), a potent DNA topoisomerase I inhibitor. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal can be utilized for the development of antibody-drug conjugates (ADCs).
-
Val-Cit-Exatecan
0 ImagesCat. No.: HY-160756CAS No.: 2952679-21-7Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma.
-
Mal-Phe-C4-VC-PAB-DMEA-PNU-159682
0 ImagesCat. No.: HY-126689CAS No.: 2259318-54-0Mal-Phe-C4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-Phe-C4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.
-
ADC-5 drug-linker
0 ImagesCat. No.: HY-176455ADC-5 drug-linker (Compound linker-payload 5) is a drug-linker conjugate for ADC with potent anti-tumor activity. ADC-5 drug-linker can be used to synthesize NLRP3 agonist 3 (HY-176452).
-
Maytansine derivative M24
0 ImagesCat. No.: HY-171125CAS No.: 2226467-81-6Maytansine derivative M24 is an ADC Drug-Linker Conjugates for ADC that can be used to synthesize ADC REGN5093-M114.
-
Mal-PEG2-Val-Arg-PABC-OMe-Eribulin
0 ImagesCat. No.: HY-177953CAS No.: 2676196-79-3Mal-PEG2-Val-Arg-PABC-OMe-Eribulin (Compound L-1) is a drug-linker conjugate composed of O-Me Eribulin (HY-159576) and the linker Mal-PEG2-Val-Cit-PAB-OH (HY-130222). Mal-PEG2-Val-Arg-PABC-OMe-Eribulin can be used to synthesize anti-HER3/MET antibody-drug conjugates (ADCs).
-
N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177678N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
AMCC-DM1
0 ImagesCat. No.: HY-128951CAS No.: 1228105-53-0AMCC-DM1 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker AMCC to make antibody drug conjugate. AMCC is a noncleavable linker.
-
APL-1091
0 ImagesCat. No.: HY-169323CAS No.: 2921735-87-5Synonyms: Mal-Exo-EEVC-MMAEAPL-1091 (Mal-Exo-EEVC-MMAE) is an ADC payload-linker conjugate (Drug-Linker Conjugates for ADC). APL-1091 is formed by the conjugation of the Mal-Exo-EEVC (HY-169353) linker and MMAE (HY-15162), a microtubule inhibitor. APL-1091 resists aggregation at high drug-to-antibody ratio (DAR), exhibits excellent plasma stability, and reduces premature payload release. When conjugated with Trastuzumab (HY-P9907), APL-1091 displays anti-tumor activity in gastric cancer xenograft models. APL-1091 can be used for ADC synthesis and gastric cancer-related research.
-
β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE
![β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE](https://file.medchemexpress.com/product_pic/hy-155313.gif "Click to View β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE Product Detail")
0 ImagesCat. No.: HY-155313β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE (compound 20) is auristatins-glucuronide conjugate. Antitumor agent-122 shows in vitro antiproliferative activities against β-glucuronidase pretreated and untreated cancer cells with an IC50 value of 5.7 nM - 9.7 nM. Antitumor agent-122 shows potent antitumor efficacy in HCT-116 xenograft mouse model without inducing side effects.
-
Val-Cit-PAB-DEA-Dxd
0 ImagesCat. No.: HY-158137CAS No.: 2964543-53-9Val-Cit-PAB-DEA-Dxd (compound 81) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (DNA topoisomerase I inhibitor). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis.
-
TPA(bi(Tos))-γ-Glu(PEG23)-Glu-Val-Cit-PAB-PNU-159682
0 ImagesCat. No.: HY-184514TPA (bi (Tos))-γ-Glu (PEG23)-Glu-Val-Cit-PAB-PNU-159682 is a cleavable linker-payload conjugate, in which the payload is PNU-159682 (HY-16700) and the linker is TPA (bi (SH))-γ-Glu (PEG23)-Glu-Val-Cit-PAB (HY-184515). TPA (bi (Tos))-γ-Glu (PEG23)-Glu-Val-Cit-PAB-PNU-159682 is used to generate L1CAM-targeted antibody-drug conjugates (ADCs). TPA (bi (Tos))-γ-Glu (PEG23)-Glu-Val-Cit-PAB-PNU-159682 can be used in the research of metastatic triple-negative basal breast cancer and lung adenocarcinoma.
-
Tub114
0 ImagesCat. No.: HY-177413CAS No.: 2361406-35-9Tub114 is a drug-linker conjugate for ADC. Tub114 is a Tubulysin B (HY-N1243) analog with a stable hydrophilic linker. Tub114 can be used for synthesis of ADCs.
-
MC-AcLys-GDEVD-PABC-Exatecan
0 ImagesCat. No.: HY-185101MC-AcLys-GDEVD-PABC-Exatecan (MC-AcLys-GDEVD-PABC-DX8951) is a agent-linker conjugate for ADC. MC-AcLys-GDEVD-PABC-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with a novel caspase-3 cleavable peptide linker MC-AcLys-GDEVD-PABC linker. MC-AcLys-GDEVD-PABC-Exatecan can be used to prepare DX8951 antibody conjugate (ADC), and it exhibites significant bystander effect mediated by the caspase-3-triggered extracellular cleavage of the linker, enhancing payload release into the tumor microenvironment.
